A nephrotoxicity-free, iron-based contrast agent for magnetic resonance imaging of tumors.

ABSTRACT: Gadolinium-based contrast agents (GBCAs) are the most widely used T₁ contrast agents for magnetic resonance imaging (MRI) and have achieved remarkable success in clinical cancer diagnosis. However, GBCAs could cause severe nephrogenic systemic fibrosis to patients with renal insufficiency. Nevertheless, GBCAs are quickly excreted from the kidneys, which shortens their imaging window and prevents long-term monitoring of the disease per injection. Herein, a nephrotoxicity-free T₁ MRI contrast agent is developed by coordinating ferric iron into a telodendritic, micellar nanostructure. This new nano-enabled, iron-based contrast agent (nIBCA) not only can reduce the renal accumulation and relieve the kidney burden, but also exhibit a significantly higher tumor to noise rat

SUBMITTER: Xue X 

PROVIDER: S-EPMC7442595 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature